Cytomegalovirus immediate-early 1 (IE1) peptide–human leukocyte antigen (HLA) complex (CMV IE1-HLA complex)

The Cytomegalovirus (CMV) immediate-early 1 (IE1) peptide–HLA complex is a critical molecular target for the cellular immune system's control of CMV infection. IE1 is one of the first proteins expressed during viral reactivation or primary infection and is essential for viral replication and the antagonism of host intrinsic immunity, such as the PML-mediated defense (PLoS Pathogens, 2021). Peptides derived from the IE1 protein are processed and presented on the cell surface by Human Leukocyte Antigen (HLA) Class I and Class II molecules, where they are recognized by the T-cell receptors (TCRs) of CD8+ and CD4+ T cells, respectively (NIH, 2007). This recognition triggers a potent immune response, including the release of interferon-gamma and the direct lysis of infected cells. In clinical settings, these complexes are targeted by various immunotherapeutic strategies, including adoptive transfer of virus-specific T cells (VSTs), TCR-engineered T cells (TCR-T), and peptide-based or viral-vector vaccines like AdIE1 (NIH, 2024). A significant challenge in targeting these complexes is the high degree of HLA polymorphism, which restricts the efficacy of specific peptide-targeted therapies to patients with matching HLA alleles (NIH, 2020).

Other names

CMV IE1 peptide-MHC complexIE1-HLA complexHCMV IE1-derived peptide-HLA complexCytomegalovirus IE1-derived peptide–HLA class I/II complexes

T-cell receptor (TCR) mediated recognition and activation of cytotoxic T lymphocytes (CTLs) leading to lysis of CMV-infected cells.